Download PDF
Semin Thromb Hemost 2022; 48(04): 465-480
DOI: 10.1055/s-0042-1748152
Review Article

Risk Factors for Major Adverse Cardiovascular Events and Major Adverse Limb Events after Venous Thromboembolism: A Large Prospective Cohort Study

Steve Raoul Noumegni
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Romain Didier
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
3   Department of Cardiology, Brest Teaching Hospital, Brest, France
,
Vincent Mansourati
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
3   Department of Cardiology, Brest Teaching Hospital, Brest, France
,
Emmanuelle Le Moigne
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Raphael Le Mao
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Clément Hoffmann
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Claire De Moreuil
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Cécile Tromeur
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Pierre-Yves Le Roux
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
4   Department of Nuclear Medicine, Brest Teaching Hospital, Brest, France
,
Bahaa Nasr
5   Department of Vascular Surgery, Brest Teaching Hospital, Brest, France
,
Jean-Christophe Gentric
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
6   Department of Neuroradiology, Brest Teaching Hospital, Brest, France
,
Marie Guegan
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Elise Poulhazan
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Karine Lacut
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Luc Bressollette
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
,
Francis Couturaud
1   Departments of Internal Medicine, Vascular Medicine and Pneumology, Brest University Teaching Hospital, Brest Teaching Hospital, Brest, France
2   Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France
› Author Affiliations Funding The study was supported by grants from the “Programme Hospitalier de Recherche Clinique” (French Department of Health), the Foundation “Archipel Santé” and the sponsor was the Brest Teaching Hospital. The funding source was not involved in designing or conducting the study; collecting, managing, analyzing, or interpreting the data; preparing, reviewing, or approving the manuscript; or deciding to submit this for publication. An academic steering committee led by F.C. assumed overall responsibility for all these steps. F.C. reported having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, InterMune, and Actelion.
› Further Information
    Permissions and Reprints

Abstract

Background There is an increased risk of arterial events including major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after venous thromboembolism (VTE). However, their risk factors remain little explored.

Methods We aimed to determine the risk factors for MACE (acute coronary syndrome/stroke/cardiovascular death) and MALE (limb ischemia/critical limb ischemia/non-traumatic amputation/any limb revascularization) after VTE. Competing risk models (Fine-Gray) were used in a multicenter prospective cohort of 4,940 patients (mean age: 64.6 years and median follow-up: 64 months).

Results MACE occurred in 17.3% of participants (2.35% per patient-years) and MALE in 1.7% (0.27% per patient-years). In multivariable analysis, the identified risk factors for MACE were the age of 50 to 65 years (vs. <50 years, hazard ratio [HR]: 2.00, 95% confidence interval [CI]: 1.38–2.91), age >65 years (vs. <50 years, HR 4.85, 95% CI: 3.35–7.02), pulmonary embolism + deep vein thrombosis (DVT) (vs. isolated-DVT, HR: 1.25, 95% CI: 1.02–1.55), unprovoked-VTE (vs. transient risk factor associated-VTE, HR: 1.29, 95% CI: 1.04–1.59), current tobacco use (vs. never, HR: 1.45, 95% CI: 1.07–1.98), hypertension (HR: 1.61, 95% CI: 1.30–1.98), past history of symptomatic atherosclerosis (HR: 1.52, 95% CI: 1.17–1.98), heart failure (HR: 1.71, 95% CI: 1.21–2.42), atrial fibrillation (HR: 1.55, 95% CI: 1.15–2.08), and vena cava filter insertion (HR: 1.46, 95% CI: 1.03–2.08). The identified risk factors for MALE were the age of 50–65 years (vs. <50 years, HR: 3.49, 95% CI: 1.26–9.65) and atrial fibrillation (HR: 2.37, 95% CI: 1.15–4.89).

Conclusions Risk factors for MACE and MALE after VTE included some traditional cardiovascular risk factors, patient's comorbidities, and some characteristics of VTE.

Keywords

venous thromboembolism - arterial cardiovascular event - MACE - MALE - prospective cohort

Ethics Approval and Consent to Participate

The study was approved by the Ethics Committee of Brest University Teaching Hospital (CCP-Ouest 6-390) with the last amendment approved on November 20, 2013 under reference number: EDITH II/RB 05.003. All participants signed a consent form.


Patient and Public Involvement

Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.


Availability of Data and Materials

The data that support the findings of this study are available from SRN or FC, upon reasonable request.


Author's Contributions

S.R.N., F.C., L.B., R.D., C.D.M., K.L., and E.L.M. were responsible for conception and design; E.P. for acquisition of data; S.R.N. for data analysis; S.R.N., F.C., and L.B. for the analysis and interpretation of data; S.R.N. for manuscript drafting; all authors for manuscript revision; all authors for the approval of the final version of the manuscript; F.C. for obtaining funding; F.C., C.T., R.D., K.L., R.L.M., and E.L.M. for administrative, technical, and material support; F.C. for study supervision; F.C. and S.R.N. for full access to all the data of the study; and all authors were responsible for all aspect of the study, reliability, and freedom from bias of the data presented.


Supplementary Material



Publication History

Article published online:
30 June 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Adelborg K, Sundbøll J, Sørensen HT. Arterial cardiovascular events and mortality following venous thromboembolism. Ann Transl Med 2015; 3 (09) 117
    PubMedGoogle Scholar
  • 2 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 3-14
    CrossrefPubMedGoogle Scholar
  • 3 Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38 (4, Suppl): S495-S501
    CrossrefPubMedGoogle Scholar
  • 4 Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370 (9601): 1773-1779
    CrossrefPubMedGoogle Scholar
  • 5 Lind C, Flinterman LE, Enga KF. et al. Impact of incident venous thromboembolism on risk of arterial thrombotic diseases. Circulation 2014; 129 (08) 855-863
    CrossrefPubMedGoogle Scholar
  • 6 Rinde LB, Småbrekke B, Mathiesen EB. et al. Ischemic stroke and risk of venous thromboembolism in the general population: the Tromsø Study. J Am Heart Assoc 2016; 5 (11) e004311
    CrossrefPubMedGoogle Scholar
  • 7 Rinde LB, Lind C, Småbrekke B. et al. Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost 2016; 14 (06) 1183-1191
    CrossrefPubMedGoogle Scholar
  • 8 Moheimani F, Jackson DE. Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol 2011 DOI: 10.5402/2011/124610
    CrossrefPubMedGoogle Scholar
  • 9 Ljungqvist M, Holmström M, Kieler H, Odeberg J, Lärfars G. Cardiovascular disease and mortality after a first episode of venous thromboembolism in young and middle-aged women. Thromb Res 2016; 138: 80-85
    CrossrefPubMedGoogle Scholar
  • 10 Noumegni SR, Hoffmann C, Tromeur C. et al. Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: a systematic review and meta-analysis of cohort studies. Thromb Res 2021; 203: 172-185
    CrossrefPubMedGoogle Scholar
  • 11 Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010; 8 (05) 891-897
    CrossrefPubMedGoogle Scholar
  • 12 Golemi I, Cote L, Iftikhar O. et al; Registro Informatizado de Enfermedad Tromboembólica Investigators. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: findings from the Registro Informatizado de Enfermedad Tromboembólica Registry. J Vasc Surg Venous Lymphat Disord 2020; 8 (03) 353-359.e1
    CrossrefPubMedGoogle Scholar
  • 13 Chang W-T, Chang C-L, Ho C-H, Hong C-S, Wang J-J, Chen Z-C. Long-term effects of unprovoked venous thromboembolism on mortality and major cardiovascular events. J Am Heart Assoc 2017; 6 (05) e005466
    CrossrefPubMedGoogle Scholar
  • 14 Laliberté F, Nutescu EA, Lefebvre P. et al. Risk factors associated with myocardial infarction in venous thromboembolism patients. Curr Med Res Opin 2014; 30 (01) 27-35
    CrossrefPubMedGoogle Scholar
  • 15 Noumegni SR, Hoffmann C, Tromeur C. et al. Risk factors of arterial events in patients with venous thromboembolism: a systematic review and meta-analysis. Thromb Haemost 2021; (e-pub ahead of print) DOI: 10.1055/s-0041-1732300.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Delluc A, Tromeur C, Le Moigne E. et al. Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thromb Res 2012; 130 (06) 859-863
    CrossrefPubMedGoogle Scholar
  • 17 Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998; 128 (08) 663-677
    CrossrefPubMedGoogle Scholar
  • 18 Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359 (26) 2804-2813
    CrossrefPubMedGoogle Scholar
  • 19 Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii , 1–253
    PubMedGoogle Scholar
  • 20 Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJG. eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 2009; 20 (07) 722-727
    CrossrefPubMedGoogle Scholar
  • 21 Dehmer GJ, Badhwar V, Bermudez EA. et al. 2020 AHA/ACC key data elements and definitions for coronary revascularization: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Coronary Revascularization). Circ Cardiovasc Qual Outcomes 2020; 13 (04) e000059
    CrossrefPubMedGoogle Scholar
  • 22 Sacco RL, Kasner SE, Broderick JP. et al; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44 (07) 2064-2089
    Google Scholar
  • 23 Hicks KA, Mahaffey KW, Mehran R. et al; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol 2018; 71 (09) 1021-1034
    CrossrefPubMedGoogle Scholar
  • 24 Hicks KA, Tcheng JE, Bozkurt B. et al; ACC/AHA TASK FORCE ON CLINICAL DATA STANDARDS MEMBERS. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol 2015; 22 (05) 1041-1144
    CrossrefPubMedGoogle Scholar
  • 25 Olinic D-M, Stanek A, Tătaru D-A, Homorodean C, Olinic M. Acute Limb ischemia: an update on diagnosis and management. J Clin Med 2019; 8 (08) 1215
    CrossrefPubMedGoogle Scholar
  • 26 Kinlay S. Management of critical limb ischemia. Circ Cardiovasc Interv 2016; 9 (02) e001946
    CrossrefPubMedGoogle Scholar
  • 27 Stegherr R, Schmoor C, Lübbert M, Friede T, Beyersmann J. Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events. Pharm Stat 2021; 20 (06) 1125-1146
    CrossrefPubMedGoogle Scholar
  • 28 Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16 (03) 1141-1154
    CrossrefPubMedGoogle Scholar
  • 29 Le Moigne E, Timsit S, Ben Salem D. et al. Patent foramen ovale and ischemic stroke in patients with pulmonary embolism: a prospective cohort study. Ann Intern Med 2019; 170 (11) 756-763
    CrossrefPubMedGoogle Scholar
  • 30 Bilora F, Ceresa M, Milan M, Sarolo L, Prandoni P. The impact of deep vein thrombosis on the risk of subsequent cardiovascular events: a 14-year follow-up study. Int Angiol 2017; 36 (02) 156-159
    CrossrefPubMedGoogle Scholar
  • 31 Go AS, Reynolds K, Yang J. et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study. JAMA Cardiol 2018; 3 (07) 601-608
    CrossrefPubMedGoogle Scholar
  • 32 Tang L, Wu Y-Y, Lip GYH, Yin P, Hu Y. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 2016; 3 (01) e30-e44
    CrossrefPubMedGoogle Scholar
  • 33 Lutsey PL, Norby FL, Alonso A. et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. J Thromb Haemost 2018; 16 (04) 670-679
    CrossrefPubMedGoogle Scholar
  • 34 Pasha SM, Tan M, van Rees Vellinga TFD, Klok FA, Huisman MV. Risk of atherothrombotic events in patients after proximal deep-vein thrombosis. Blood Coagul Fibrinolysis 2016; 27 (01) 13-18
    CrossrefPubMedGoogle Scholar
  • 35 Spencer FA, Ginsberg JS, Chong A, Alter DA. The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost 2008; 6 (09) 1507-1513
    CrossrefPubMedGoogle Scholar
  • 36 Couturaud F, Pernod G, Presles E. et al; “PADIS-DVT” investigators. Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial. Haematologica 2019; 104 (07) 1493-1501
    CrossrefPubMedGoogle Scholar
  • 37 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Executive Summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160 (06) 2247-2259
    CrossrefPubMedGoogle Scholar